GSK Statistics
Total Valuation
GSK has a market cap or net worth of $118.78 billion. The enterprise value is $137.48 billion.
Important Dates
The last earnings date was Wednesday, February 4, 2026, before market open.
| Earnings Date | Feb 4, 2026 |
| Ex-Dividend Date | Feb 20, 2026 |
Share Statistics
GSK has 4.01 billion shares outstanding. The number of shares has decreased by -0.60% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.01B |
| Shares Change (YoY) | -0.60% |
| Shares Change (QoQ) | -0.39% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 86.44% |
| Float | 3.87B |
Valuation Ratios
The trailing PE ratio is 31.65 and the forward PE ratio is 12.45.
| PE Ratio | 31.65 |
| Forward PE | 12.45 |
| PS Ratio | 2.70 |
| Forward PS | 3.46 |
| PB Ratio | 5.53 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 13.80 |
| P/OCF Ratio | 11.40 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 7.73, with an EV/FCF ratio of 15.98.
| EV / Earnings | 17.87 |
| EV / Sales | 3.13 |
| EV / EBITDA | 7.73 |
| EV / EBIT | 10.83 |
| EV / FCF | 15.98 |
Financial Position
The company has a current ratio of 0.82, with a Debt / Equity ratio of 1.11.
| Current Ratio | 0.82 |
| Quick Ratio | 0.52 |
| Debt / Equity | 1.11 |
| Debt / EBITDA | 1.34 |
| Debt / FCF | 2.77 |
| Interest Coverage | 13.46 |
Financial Efficiency
Return on equity (ROE) is 43.31% and return on invested capital (ROIC) is 26.51%.
| Return on Equity (ROE) | 43.31% |
| Return on Assets (ROA) | 9.78% |
| Return on Invested Capital (ROIC) | 26.51% |
| Return on Capital Employed (ROCE) | 23.74% |
| Weighted Average Cost of Capital (WACC) | 5.35% |
| Revenue Per Employee | $640,638 |
| Profits Per Employee | $112,097 |
| Employee Count | 68,629 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.54 |
Taxes
In the past 12 months, GSK has paid $1.50 billion in taxes.
| Income Tax | 1.50B |
| Effective Tax Rate | 15.02% |
Stock Price Statistics
The stock price has increased by +58.10% in the last 52 weeks. The beta is 0.27, so GSK's price volatility has been lower than the market average.
| Beta (5Y) | 0.27 |
| 52-Week Price Change | +58.10% |
| 50-Day Moving Average | 52.94 |
| 200-Day Moving Average | 44.47 |
| Relative Strength Index (RSI) | 61.83 |
| Average Volume (20 Days) | 6,876,029 |
Short Selling Information
The latest short interest is 17.72 million, so 0.88% of the outstanding shares have been sold short.
| Short Interest | 17.72M |
| Short Previous Month | 14.91M |
| Short % of Shares Out | 0.88% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.64 |
Income Statement
In the last 12 months, GSK had revenue of $43.97 billion and earned $7.69 billion in profits. Earnings per share was $1.87.
| Revenue | 43.97B |
| Gross Profit | 31.92B |
| Operating Income | 12.69B |
| Pretax Income | 9.96B |
| Net Income | 7.69B |
| EBITDA | 17.78B |
| EBIT | 12.69B |
| Earnings Per Share (EPS) | $1.87 |
Full Income StatementBalance Sheet
The company has $4.58 billion in cash and $23.85 billion in debt, with a net cash position of -$19.27 billion or -$4.80 per share.
| Cash & Cash Equivalents | 4.58B |
| Total Debt | 23.85B |
| Net Cash | -19.27B |
| Net Cash Per Share | -$4.80 |
| Equity (Book Value) | 21.48B |
| Book Value Per Share | 5.49 |
| Working Capital | -5.22B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $10.42 billion and capital expenditures -$1.81 billion, giving a free cash flow of $8.60 billion.
| Operating Cash Flow | 10.42B |
| Capital Expenditures | -1.81B |
| Free Cash Flow | 8.60B |
| FCF Per Share | $2.14 |
Full Cash Flow StatementMargins
Gross margin is 72.61%, with operating and profit margins of 28.87% and 17.50%.
| Gross Margin | 72.61% |
| Operating Margin | 28.87% |
| Pretax Margin | 22.66% |
| Profit Margin | 17.50% |
| EBITDA Margin | 40.44% |
| EBIT Margin | 28.87% |
| FCF Margin | 19.57% |
Dividends & Yields
This stock pays an annual dividend of $1.75, which amounts to a dividend yield of 2.97%.
| Dividend Per Share | $1.75 |
| Dividend Yield | 2.97% |
| Dividend Growth (YoY) | 14.49% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 93.86% |
| Buyback Yield | 0.60% |
| Shareholder Yield | 3.57% |
| Earnings Yield | 6.48% |
| FCF Yield | 7.24% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 3.47% |
| EPS Growth Forecast (5Y) | 9.59% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on July 19, 2022. It was a reverse split with a ratio of 1:1.25.
| Last Split Date | Jul 19, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:1.25 |
Scores
GSK has an Altman Z-Score of 2.02 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.02 |
| Piotroski F-Score | 7 |
